🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Sweden / NCT02720302
Active, not recruiting Not applicable

Treatment of Overweight in Children on Distance

NCT02720302 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2016-03
Last updated
2026-05-04

Condition(s) studied

Overweight

Investigational drug(s) / intervention(s)

SOFTTeleSOFT

SOFT: SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.

TeleSOFT: The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.

Study summary

The present study is a public health project with the aim to treat overweight in children 9-11 years of age. After the first consultation the children are randomized to either continue the treatment at The Child Obesity Clinic, Child Department or to have the following 2-3 consultations on distance with Lync. Last visit for all children is on the Child Obesity Clinic after approximately 12 months. Follow up after at least 1 years will be performed.

Eligibility

Sex
ALL
Min age
9 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: \- Children with overweight and not obese according to the definitions developed by Cole et al (4). It implies that we include children with the following age specific BMI Inclusion criteria * 9 years = AGE \< 9 years, 6 months AND 19,0\< BMI\<23,0 * 9 years, 6 months =\> AGE \< 10 Years AND 19,5 \<BMI\<23,5 * 10 years = AGE \< 10 years, 6 months AND 20,0\<BMI\<24,0 * 10 years, 6 months=\>AGE\< 11 years AND 20,5\<BMI\<24,5 * 11 years = AGE \< 11 years, 6 months AND 21,0\<BMI\<25,5 * 11 years, 6 months =\>AGE\<12 years AND 21,5\<BMI\<25,5 Exclusion Criteria: * Children and his/her parents not able to communicate in Swedish. * Children with monogenic obesity * Present less than 80% at school in the latest school year. * No foster care for the child or his/her brothers or sisters

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Barnmedicin Malmö Skåne County

More Skane University Hospital trials in Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02720302 on ClinicalTrials.gov ↗ ← All trials in Sweden